Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464935 | 0.82 | CCR1 (0.50) | KCNH2BACE1FFAR1NOS1NOS2 | |
| SCHEMBL5020478 | 0.81 | NPC1 (0.33) | KCNH2FFAR1 | |
| SCHEMBL4562000 | 0.79 | RECQL (0.49) | FFAR1 | |
| SCHEMBL5020447 | 0.79 | CCR1 (0.33) | KCNH2FFAR1CCR1CCR8 | |
| SCHEMBL15465206 | 0.79 | CCR1 (0.33) | KCNH2FFAR1CCR1CCR8 | |
| SCHEMBL5020231 | 0.79 | HSP90AA1 (0.36) | KCNH2FFAR1 | |
| SCHEMBL5020316 | 0.79 | FFAR1 (0.39) | FFAR1CCR1CCR8PDE10A | |
| SCHEMBL10289683 | 0.78 | PPARG (0.32) | KCNH2FFAR1NOS1NOS2 | |
| SCHEMBL5020233 | 0.78 | PPARG (0.31) | — | |
| SCHEMBL15470588 | 0.76 | CCR1 (0.59) | FFAR1CCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012062844-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | KCNH2 2388/4885BACE1 1547/4885FFAR1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.